Enhanced recovery after single-site robotic staging surgery of endometrial cancer.

This retrospective study aimed to examine the safety and clinical outcomes of enhanced recovery after single-site robotic staging surgery in patients with endometrial cancer. Data were collected from Seoul St. Mary's Hospital's electronic medical records between July 2017 and August 2021. All the included endometrial cancer patients underwent single-site robotic staging surgery followed by enhanced recovery after surgery based on the guidelines for enhanced recovery after surgery society recommendations. The factors assessed were survival outcomes, complications and postoperative adjuvant therapy. Of the 60 patients included in this study, four (6.7%) experienced grade III postoperative complications within 30 days after surgery. Additionally, there were five cases (8.3%) that required a visit to the emergency room and two cases (3.3%) that necessitated readmission. Seventeen patients (28.3%) received postoperative adjuvant therapy, with treatment initiated 8 weeks after staging surgery in 14 patients (23.3%) and over 8 weeks in three patients (5.0%). The follow-up duration averaged 32.0 months (range, 3 to 60 months). No mortality was recorded during the follow-up period after staging surgery. The recurrence rate was 5.0% (n = 3), and the 3- year progression-free survival rate for the endometrioid type was 94.3%. These findings suggest that enhanced recovery after single-site robotic staging surgery is feasible for patients with endometrial cancer, yielding similar clinical outcomes and manageable complications without extending the time to adjuvant therapy initiation. However, further studies are necessary to investigate the long-term survival outcomes associated with enhanced recovery after surgery application. [ABSTRACT FROM AUTHOR]